Tom John

Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial.

Juliann Chmielecki, Tony Mok, Yi-Long Wu, Ji-Youn Han, Myung-Ju Ahn, Suresh S Ramalingam, Thomas John, Isamu Okamoto, James Chih-Hsin Yang, Frances A Shepherd, Krishna C Bulusu, Gianluca Laus, Barbara Collins, J Carl Barrett, Ryan J Hartmaier, Vassiliki Papadimitrakopoulou

Journal article  |  2023  |  Nat Commun

Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), potently and selectively inhibits EGFR-TKI-..

Predicting response to immune checkpoint blockade in NSCLC with tumour-only RNA-seq

John F Markham, Andrew P Fellowes, Thomas Green, Jose Luis Leal, Roxane Legaie, Darren Cullerne, Tessa Morris, Tom John, Ben Solomon, Stephen B Fox

Journal article  |  2022  |  BRITISH JOURNAL OF CANCER

BACKGROUND: Targeted RNA sequencing (RNA-seq) from FFPE specimens is used clinically in cancer for its ability to estimate gene ex..

Immunotherapy in Advanced NSCLC Without Driver Mutations: Available Therapeutic Alternatives After Progression and Future Treatment Options

Jose Luis Leal, Thomas John

Journal article  |  2022  |  CLINICAL LUNG CANCER

The treatment paradigm of non-small-cell lung cancer without oncogenic drivers has varied dramatically in recent years and is cons..

ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with 89Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol.

Fiona Hegi-Johnson, Stacey E Rudd, Christian Wichmann, Tim Akhurst, Peter Roselt, Jenny Trinh, Thomas John, Lisa Devereux, Paul S Donnelly, Rod Hicks, Andrew M Scott, Daniel Steinfort, Stephen Fox, Benjamin Blyth, Sagun Parakh, Gerard G Hanna, Jason Callahan, Kate Burbury, Michael MacManus

Journal article  |  2022  |  BMJ Open

BACKGROUND: ImmunoPET is a multicentre, single arm, phase 0-1 study that aims to establish if 89Zr-durvalumab PET/CT can be used t..

SMARCB1/INI1-deficient primary lung carcinoma with hepatic metastasis

James A Rickard, Marian L Burr, Bernadette Williams, Anand Murugasu, Andrew Fellowes, Thomas John, Michael Christie

Journal article  |  2022  |  PATHOLOGY

P1.10-02 ImmunoPET: A Phase 0/1 Study Characterising PD-L1 with 89Zr-Durvalumab (MEDI4736) PET/CT in Stage III NSCLC Patients Receiving Chemoradiation

M MacManus, S Rudd, P Roselt, C Wichmann, J Callahan, T John, A Scott, P Donnelly, G Hanna, F Hegi-Johnson

Journal article  |  2022  |  Journal of Thoracic Oncology

MA09.05 Increased PD-L1 Tracer Uptake in Recently-irradiated Lesions in NSCLC: Preliminary Results of a Phase 0 Trial (ImmunoPET) of a Novel PET Tracer

F Hegi-Johnson, T Akhurst, S Rudd, P Donnelly, A Scott, J Callahan, P Roselt, T John, S Sithara, C Wichmann, G Hanna, M MacManus

Journal article  |  2022  |  Journal of Thoracic Oncology

P2.03-01 Initial Biodistribution Data of ImmunoPET A Phase 0/1 Study Characterising PD-L1 with 89 Zr-Durvalumab (MEDI4736) PET/CT

F Hegi-Johnson, S Rudd, J Callahan, C Wichmann, T Akhurst, P Roselt, T John, P Donnelly, A Scott, G Hanna, M MacManus

Journal article  |  2022  |  Journal of Thoracic Oncology

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC.

Alexander Drilon, Chao-Hua Chiu, Yun Fan, Byoung Chul Cho, Shun Lu, Myung-Ju Ahn, Matthew G Krebs, Stephen V Liu, Thomas John, Gregory A Otterson, Daniel SW Tan, Tejas Patil, Rafal Dziadziuszko, Erminia Massarelli, Takashi Seto, Robert C Doebele, Bethany Pitcher, Nino Kurtsikidze, Sebastian Heinzmann, Salvatore Siena

Journal article  |  2022  |  JTO Clin Res Rep

INTRODUCTION: Entrectinib is an approved tyrosine kinase inhibitor (TKI) for ROS1 fusion-positive NSCLC. An updated integrated ana..

Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial

Margarita Majem, Jonathan W Goldman, Thomas John, Christian Grohe, Konstantin Laktionov, Sang-We Kim, Terufumi Kato, Huu Vinh Vu, Shun Lu, Shanqing Li, Kye Young Lee, Charuwan Akewanlop, Chong-Jen Yu, Filippo de Marinis, Laura Bonanno, Manuel Domine, Frances A Shepherd, Shinji Atagi, Lingmin Zeng, Dakshayini Kulkarni, et al.

Journal article  |  2022  |  CLINICAL CANCER RESEARCH

PURPOSE: In the phase III ADAURA trial, adjuvant treatment with osimertinib versus placebo, with/without prior adjuvant chemothera..